News & Announcements
Congratulations to Nathaniel Shannon,
a CMB graduate student,
received one of eight annual Trainee Awards from the Society for Redox
Biology and Medicine (SfRBM) for his abstract, titled “Miro1-mediated
mitochondrial positioning supports subcellular redox status.” The
awards—made available to students and postdoctoral fellows who wish to
attend SfRBM to present their research—are conferred based on quality
and the scientific merit of a submitted abstract. The 2021 recipients
were awarded $500 each and were recognized during the 2021 SfRBM Virtual
Conference held November 15to-18.
In addition, each awardee received a voucher for free registration to
either the 2022 or 2023 conference. (12/2021)
Heading to clinical trials..."UVM researchers celebrate ‘first-of-its-kind’ mesothelioma treatment headed to clinical trials" – My Champlain Valley News. University of Vermont researchers have made a breakthrough in their study of possible treatments for malignant mesothelioma, a rare and aggressive cancer linked to asbestos exposure. (10/2021)
Terri Messier, Research Analyst and Lab Manager of the Cunniff lab has been highlighted in the "Meet the Staff" section in the October 20, 2021 | Volume III, Issue 20 of the Larner College of Medicine Dean's Newsletter. (10/2021)
Terri Messier, Research Analyst and Lab Manager of the Cunniff lab was recently awarded a Dean's Excellence in Research Award from the Larner College of Medicine. Terri has served the UVM community for over 25 years both as a scientist and steward of professionalism. Terri is a rigorous, creative and skilled scientist. She has authored 18 manuscripts, contributed to numerous patent applications and mentored an abundance of students. Terri serves on the UVM Laboratory Safety Partnership, the Youth Workforce Development Grad Challenge and is a member of the Vermont Biosciences Alliance. Terri is actively involved in the larger Chittenden county community, directing the Vermont Cancer Center Community Outreach Program that brings high school students into LCOM research labs and provides them with early exposure to science and research. Terri is a driving factor in the continuing success of our research and a role model for a dedicated and professional research scientist. Congratulations Terri!! (11/2020)
Congratulations!
to Meara for her presentation during the Virtual Student Research
Conference! Meara has been conducting her Honors College Undergraduate
Research in the lab since the spring of 2018. She has received two
competitive undergraduate
research awards to support her research. We look forward to her
completing her Thesis work in 2021! See Meara's poster here.
The Cunniff Lab recently received funding from the Butler Family Foundation (managed by the Community Foundation for the Greater Capital Region) to investigate malignant mesothelioma tumor profiles that may predict sensitivity to therapies currently being developed in the Cunniff Lab, with support from RS Oncology. Malignant mesothelioma is a devastating disease that has no cure and is one of the most difficult tumors to treat. RS Oncology, in collaboration with the Cunniff Lab, is developing a therapeutic approach utilizing a novel mechanism of action that has shown promising pre-clinical activity.
This generous gift from the Butler Family will help to identify patients who are most likely to respond to current and new therapies under development. We are very thankful to the Butler Family for their generous support!
"Innovative Partnership"
“Brian attended the European Society for Medical Oncology Congress in Barcelona, Spain with members of RS Oncology (George Naumov, COO and Jarrett Duncan, CEO) to announce a partnership with Azierta Scientific Consulting for co-development of RS Oncology’s novel therapeutic (PER-016) targeting mitochondrial oxidative stress signaling pathways in ovarian cancer. Pre-clinical data supporting the development of this therapeutic approach originated with work from Dr. Heintz and Cunniff and is ongoing in the Cunniff Lab.”
“This innovative partnership will allow us to expand into additional indications currently outside of our corporate strategy. This will ultimately speed up the process of reaching as many patients as possible sooner than anticipated with our exciting and potentially life-changing therapy,” stated Jarrett Duncan, CEO of RS Oncology. (Oct. 2019)
Alshaabi H, Heininger M, Cunniff B.
J Biochem. 2019 Jul 29.